Overexpressing IRS1 in Endothelial Cells Enhances Angioblast Differentiation and Wound Healing in Diabetes and Insulin Resistance
The effect of enhancing insulin’s actions in endothelial cells (ECs) to improve angiogenesis and wound healing was studied in obesity and diabetes. Insulin receptor substrate 1 (IRS1) was overexpressed in ECs using the VE-cadherin promoter to create ECIRS1 TG mice, which elevated pAkt activation and expressions of vascular endothelial growth factor (VEGF), Flk1, and VE-cadherin in ECs and granulation tissues (GTs) of full-thickness wounds. Open wound and epithelialization rates and angiogenesis significantly improved in normal mice and high fat (HF) diet–induced diabetic mice with hyperinsulinemia in ECIRS1 TG versus wild type (WT), but not in insulin-deficient diabetic mice. Increased angioblasts and EC numbers in GT of ECIRS1 mice were due to proliferation in situ rather than uptake. GT in HF-fed diabetic mice exhibited parallel decreases in insulin and VEGF-induced pAkt and EC numbers by >50% without changes in angioblasts versus WT mice, which were improved in ECIRS1 TG mice on normal chow or HF diet. Thus, HF-induced diabetes impaired angiogenesis by inhibiting insulin signaling in GT to decrease the differentiation of angioblasts to EC, which was normalized by enhancing insulin’s action targeted to EC, a potential target to improve wound healing in diabetes and obesity.
Every step of the complex process of wound healing has been reported to be defective, including impairments of neutrophil activation and responses, fibroblast migration and proliferation, and angiogenesis (1–5). Poor glycemic control, neuropathy, presence of micro- and macrovascular complications, and insulin resistance are associated with impaired wound healing (6). Most strategies devised to improve chronic wound healing in patients with diabetes have not exhibited clear efficacy, possibly due to a lack of full understanding of the mechanisms induced by diabetes to impair the wound healing process (5–8).
One major factor that contributes to impaired wound healing in diabetic and insulin-resistant states is reduced angiogenesis in the granulation tissue (GT), which could be the result of decreased vascular endothelial growth factor (VEGF) expression or its actions in response to hypoxia (4,9,10). Multiple metabolic abnormalities can affect VEGF expression and actions, including hyperglycemia-related oxidative stress, glycation products, and activation of protein kinase C (PKC) (10–13). Systemic insulin resistance could also affect angiogenesis because insulin’s signaling can regulate VEGF expression, which has been reported to be inhibited in diabetes (14,15). Thus, we postulate that insulin resistance may exist in the GT to impair angiogenesis, by inhibiting insulin signaling to enhance VEGF expression and actions.
Insulin receptors are present in many cells of the GT, including keratinocytes, fibroblasts, endothelial cells (ECs), and inflammatory cells (16–21). Mice with deletion of insulin receptors in the fibroblasts and myocardium exhibited decreases in VEGF expression and capillary density in response to hypoxia (14). Insulin can induce VEGF expression mostly through the IRS1/PI3K/Akt pathway, which is selectively inhibited in insulin resistance and diabetes (14,15,22–24). Activation of pAkt affected VEGF secretion in keratinocytes and angiogenesis in cutaneous wound healing (25–27). The finding that insulin resistance may impair wound healing also suggests that differential pathogenic mechanisms may exist for defective wound healing associated with diabetes due to insulin deficiency or resistance with hyperinsulinemia. This study investigated the regulation of the insulin signaling pathway in GT and on the differentiation of angioblasts to ECs in the GT using rodent diabetic models of insulin deficiency or hyperinsulinemia and insulin resistance.
Research Design and Methods
Wild-type (WT) C57/BL6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Recombinant human VEGF (R&D Systems, Minneapolis, MN) and antibodies to pAkt, Akt, pErk, Erk1/2, fibronectin, IRS1 (Cell Signaling, Danvers, MA), VCAM1 (Millipore, Billerica, MA), Flk1, eNOS (BD Biosciences, San Jose, CA), and β-actin (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were obtained commercially.
All protocols for animal use and euthanasia were approved by the Animal Care Committee of the Joslin Diabetes Center and are in accordance with National Institutes of Health (NIH) guidelines. Mice with endothelial-specific overexpression of IRS1 (ECIRS1 TG) with VE-cadherin promoter were described previously (28) (Supplementary Fig. 1A). The following primers were used for IRS1 genotyping: 5′-ATCTGCAGGCAGCTCACAAAG-3′ and 5′-CGAAGAAGCGTTTGTGCATGC-3′. Two mice models of diabetes were used. 1) For hyperinsulinemia with insulin resistance and hyperglycemia, male mice at age 4 weeks were fed with normal chow (NC) (3.3% kcal fat) or high fat (HF) (60% kcal fat) for 10 weeks (28). Insulin-deficient diabetic mice were produced by five consecutive days of intraperitoneal injection of 50 mg streptozotocin (STZ)/kg body weight (Sigma-Aldrich, St. Louis, MO), and fasting blood glucose concentrations >400 mg/dL were documented. Insulin treatment was performed using insulin pellet (LinShin Canada, Inc., Scarborough, Ontario, Canada) placed subcutaneously and with a release rate of 0.1 unit/day/insulin pellet, which was adjusted to maintain plasma glucose at 150 mg/dL range (at steady state) in STZ-induced diabetic mice for 2 weeks. Intraperitoneal glucose tolerance tests (IPGTTs) were performed as previously described (29).
Wound Healing Model
Mouse dorsal hair was depilated on the day before surgery (Nair; Church & Dwight Co., Inc., Ewing, NJ), and mice were anesthetized by isoflurane inhalation (isoflurane, USP; NOVAPLUS, Lake Forest, IL). Their dorsum was disinfected with 70% alcohol and marked with standard square template (1.0 cm2). Skin plus panniculus carnosus was excised to create a full-thickness dorsal excisional wound, which was covered with transparent, semiocclusive adhesive polyurethane dressings (Tegaderm; 3M, St. Paul, MN) and changed two times per week (30–32).
Tissue Morphometric Analysis
Digital macroscopic images of the wound were analyzed using NIH ImageJ software version 1.40 (Bethesda, MD). Standardized photographs were taken on the day of surgery and on the 3rd, 7th, 10th, and 14th days for 14 days from a standard height. Re-epithelialization and open wound surface were measured as a percentage of the initial wound area as published (30–32).
Wound kinetics were quantified as follows: open wound rate (OWR) = open wound/initial area of wound size, contraction rate (CR) = contraction/initial area of wound size, and epithelialization rate (ER) = epithelialization/initial area of wound size − contraction (30,31). On days 3, 7, and 10 postsurgery, wounds from seven to eight animals in each group were harvested as previously described (32).
For signaling studies, insulin (1 unit/kg body weight) was administrated intravenously and GTs were collected 10 min afterward. For histological studies, excised tissues were fixed in 4% formalin at 4°C. Panoramic cross-sectional digital images of each wound were examined using an FSX100 microscope (Olympus, Center Valley, CA).
Immunohistochemistry studies were performed using paraffin sections and incubated with 0.5% BSA and rabbit mAbs to CD31 (Dianova GmbH, Hamburg, CA) as primary antibody to identify EC, followed by Alexa Flour 488–conjugated secondary antibodies (Invitrogen, Gland Island, NY). Nuclei were counterstained with DAPI (Invitrogen). Quantitative fluorescent analyses were performed using an FSX100 microscope and Adobe Photoshop CS Software (San Jose, CA).
Immunoblot and Immunoprecipitation Studies
GT, frozen in dry ice, was homogenized in ice-cold tissue lysis buffer, as previously described (33). Protein concentration was determined by Bradford assay and processed as previously described (33).
Real-time PCR procedures were used to assess mRNA levels (Applied Biosystems, Grand Island, NY) and normalized to 36B4 or 18S rRNA. PCR primers used in the study are listed in Supplementary Table 1.
Culture of ECs
Lung tissues from c57/BL6J mice were used to obtain primary ECs and used between passages three and five (33,34). ECs were incubated for 16 h in DMEM containing 0.1% BSA and stimulated with 100 nmol/L insulin for 24 h. Expression of VEGF165 in media was measured by an ELISA kit (R&D Systems).
Bone Marrow Cell Transplantation
Bone marrow (BM) cells from green fluorescent protein (GFP)–expressing mice (The Jackson Laboratory) were harvested from tibias and femurs by flushing with Dulbecco’s PBS + 5% FBS and were resuspended and filtered through a 70-μm cell strainer (35). Erythrocytes were depleted using ACK lysis buffer (Lonza, Basel, Switzerland). BM cells were stained with lineage marker mix (Lin: anti-CD3e [17-A2], anti-CD4 [L3T4], anti-CD8 [53-6.72], anti-B220 [RA3-6B2], anti–TER-119, anti–Gr-1 [RB6-8C5], and anti–Mac-1 [M1/70]; eBioscience, San Diego, CA). Flow cytometry–sorted lineage-negative cells were transplanted intravenously (2 × 106 cells/mouse) into congenic recipient mice and analyzed 7 days after transplantation (36).
Evaluating Proliferation In Vivo
At 4 and 6 days postwounding, BrdU (100 μL) was injected intraperitoneally and BrdU in angioblasts or ECs from blood and GT was detected by flow cytometry after 7 days (FITC BrdU Flow Kits; BD Pharmingen, San Jose, CA) (37).
Flow Cytometry of Cells in GT
Dissected GTs were incubated with collagenase I and II, DNase, and hyaluronidase in Hepes buffer for 30 min at 37°C and then filtered through a 70-μm cell strainer with erythrocytes depleted by ACK lysis buffer. Cells were incubated with insulin (100 nmol/L) and anti-CD16/32 (BioLegend, San Diego, CA), fixed in 2% formaldehyde, and permeabilized using the Perm/Wash Buffer (BD Biosciences, San Diego, CA) followed by incubation with monoclonal antibodies: anti-CD45 for leukocyte, anti-CD31 for EC, or anti-Flk1, marker for angioblast and PI for viability. Rabbit anti-Akt and rabbit anti–phospho-Akt (Ser473) were used to detect Akt activation, which were followed with Alexa Fluor 647 goat anti-rabbit IgG. All populations were routinely k-gated to verify purity and gating. One million cells from BM or 200,000 cells from GT were analyzed using FlowJo software version 10.0 (Tree Star, Inc., Ashland, OR).
Values are expressed as mean and SEM. Student t tests were performed for comparison of two groups. One-way ANOVA, followed with Tukey-Kramer, was performed for comparisons of multiple groups using SPSS 22.0 (SPSS, Inc., Chicago, IL). A value of P < 0.05 was considered significant.
Characterization of ECIRS1 Transgenic Mice and Insulin Signaling in GT
To enhance insulin’s actions, IRS1 was overexpressed in the EC using VE-cadherin promoter to produce ECIRS1 TG mice, which elevated IRS1 expression in the EC by 170% and in the lung and retina, but not in peripheral blood mononuclear cells (Fig. 1A and Supplementary Fig. 1B and C). Metabolically, WT and ECIRS1 TG mice did not differ by glucose tolerance as measured by IPGTT and fasting plasma insulin levels (Supplementary Fig. 1D and E).
Insulin increased VEGFB mRNA expression by 240% at 1 and 3 h and protein levels in the media by 200% after 24 h in ECs from ECIRS1 TG mice versus WT mice (Fig. 1B and C). IRS1 protein expression was increased in GT from ECIRS1 TG mice by 72% as compared with WT mice (P < 0.01) (Fig. 1D). Further, Akt phosphorylation (pAkt) in the GT of ECIRS1 TG mice was significantly increased at basal (261%, P < 0.05) and after the addition of insulin (480%, P < 0.01) compared with WT (Fig. 1E), without a difference in insulin’s activation of Erk (pErk) (Fig. 1G). Expressions of eNOS, a marker of capillary density, in the GT also significantly increased by 133%, comparing ECIRS1 TG to WT mice. (Fig. 1F).
Insulin’s Actions on Wound Healing in Control and STZ-Induced Diabetic Mice
The effect of increasing IRS1 expression and insulin’s actions in EC on wound healing was evaluated by comparing OWR, CR, and ER in WT and ECRIS1 TG mice (Fig. 2A and B). The results indicated that OWR decreased more rapidly in ECRS1 TG mice versus WT mice with improvements at 3 and 7 days (P < 0.01) (Fig. 2C). CR was significantly improved on day 14 and ER was increased in ECRIS1 TG mice by 96 and 48% on 3 and 7 days, respectively (Fig. 2D and E). VEGF mRNA and FLK1 protein expressions in the GT were also increased significantly on day 7, and VE-cadherin expression was increased on day 10 (Fig. 3E). No changes in fibronectin were observed comparing ECIRS1 TG to WT mice (Fig. 3C).
STZ-induced diabetic ECIRS1 TG and WT mice had comparable weights and fasting blood glucose of >500 mg/dL during the study (Supplementary Fig. 2A and B), with comparable plasma insulin levels of <0.2 ng/mL, which were four times lower than nondiabetic mice (Supplementary Fig. 2C). STZ diabetes delayed OWR, CR, and ER significantly, compared with nondiabetic WT and ECIRS1 TG mice at 3 and 7 days (Fig. 2A–E), although no differences were observed between diabetic STZWT and STZECIRS1 TG mice. VEGF mRNA expression in the GT after 7 days of wound initiation was decreased by 38% in STZ WT versus WT mice (P < 0.05) and in STZECIRS1 versus ECIRS1 mice (P < 0.01) (Supplementary Fig. 2D). We also evaluated wound healing between STZWT mice treated with insulin (STZWTins) and STZECIRS1 mice treated with insulin (STZECIRS1ins). The results showed that OWR was decreased (P < 0.05) and ER was increased (P < 0.01) in STZECIRS1ins mice compared with STZWTins mice at 7 days after injecting (Supplementary Fig. 3A–D).
Assessment of HF Diet–Induced Diabetes and Hyperinsulinemia on Wound Healing
To determine whether diabetes and hyperinsulinemia affect wound healing, we studied HF feeding in ECIRS1 TG (ECIRS1HF) and WT (WTHF) mice. After 10 weeks of HF feeding, body weights were significantly increased in both WTHF and ECIRS1HF mice compared with NC. Fasting blood glucose levels were elevated equally in both WTHF and ECIRS1HF mice to >200 mg/dL (Supplementary Fig. 4A and B). IPGTTs were similarly elevated; fasting and postinfusion glucose levels at 15 min >500 mg/dL (Supplementary Fig. 4C). Fasting plasma insulin levels increased significantly from 0.5 to 2.5 and 3.2 ng/dL in WTHF and ECIRS1HF mice (Supplementary Fig. 4D). Fasting plasma IGF1 level also increased in ECIRS1HF and WTHF mice (Supplementary Fig. 4E). Interestingly, VEGF mRNA expressions were increased in WTHF versus WT mice (P < 0.05) and in ECIRS1HF versus ECIRS1 TG mice by 276 and to 341%, respectively (Fig. 3E). Analysis of the wound showed HF feeding delayed OWR and ER at 3 and 7 days. Further, ECIRS1HF mice had a significantly greater reduction in OWR and increased ER than WTHF mice at 3 and 7 days (Fig. 4A, B, and D). Thickness of GT measured at 7 days after surgery was greater in ECIRS1 TG versus WT mice (P < 0.01). HF feeding decreased GT thickness in both WTHF and ECIRS1HF mice (P < 0.05) (Fig. 5A and B). Immunohistological analysis of the GT showed the number of CD31+ cells, a marker for ECs and capillaries, was increased in ECIRS1 TG versus WT mice (P < 0.01). HF feeding for 10 weeks decreased CD31+ cells by 84% in WTHF versus WT mice (Fig. 5C and D) and decreased by 63% in ECIRS1HF versus ECIRS1 TG mice. However, a 290% elevation of CD31+ cell numbers was observed in ECIRS1HF versus WTHF mice (P < 0.05) (Fig. 5C and D).
Assessing HF Diet–Induced Insulin Resistance and Diabetes on Angioblast and EC Distributions in GT
To characterize the potential mechanism for the reduction of ECs in the GT associated with HF diet, the distribution of angioblasts and ECs in the GT of WT and ECIRS1 TG mice on NC and HF were characterized. Angioblasts were identified by FLK1+, PI−, CD45−, and CD31−, and ECs by CD45−, PI−, and CD31+ cell staining. Angioblast numbers increased significantly by 50% in ECIRS1 TG compared with WT mice and by 65% in ECIRS1HF versus WTHF mice (Fig. 6A and B). Interestingly, the elevations of angioblast levels were similar between NC- and HF-fed WT and ECIRS1 TG mice. EC numbers in GT increased by 95% in ECIRS1 TG versus WT mice on NC. However, HF feeding decreased EC levels by 72% in WTHF mice compared with WT mice (P < 0.01). Similarly, ECIRS1 HF-fed mice also had 64% less EC than ECIRS1 TG mice (Fig. 6A and B). However, EC levels in the GT were significantly increased by 95% in ECIRS1 TG versus WT mice (Fig. 6B). IRS1 overexpression in the EC only partially restored its reduction induced by HF feeding and diabetes with elevation of ECs by 150% in ECIRS1 HF versus WTHF mice (Fig. 6B).
DNA synthesis of ECs and angioblasts was measured by BrdU incorporation in GT and BM. Figure 7A showed that proliferation of angioblasts in the GT was increased by 47% in ECIRS1 TG versus WT mice (P < 0.05), but no differences in BrdU incorporation were noted in these cells in the BM (Fig. 7B). To determine whether the elevation of angioblasts and ECs in the GT of ECIRS1 TG mice could also be due to uptake from circulation rather than proliferation in situ, the uptake of circulating Lin− and GFP+ cells, which were negative for PI, B220, CD4, CD8, Ter119, CD11b, and Ly6G cells and isolated from BM of GFP+ mice, were infused into WT and ECIRS1 TG mice. Figure 7C and D showed that no increases of GFP+ cells in the GT of ECIRS1 TG or WT mice were observed.
Analysis of Insulin’s Signaling in Isolated Angioblasts and ECs From GT
To support the findings that insulin actions could be inhibited by HF diet and positively enhanced by IRS1 overexpression in ECs of ECIRS1 TG mice, IRS1 expressions and signal changes in pAkt were studied in angioblasts and ECs isolated from the GT. The results showed that IRS1 expression was increased specifically in the ECs of ECIRS1 TG mice by 291% (P < 0.01), but not in the angioblasts (Fig. 8A and B). IRS1 expression was associated with the expression of VE-cadherin since its promoter was used in the transgene to make ECIRS1 TG mice (Supplementary Fig. 1A). VE-cadherin expressions were only observed in ECs but not in angioblasts (Fig. 8C). The levels of pAkt stimulated by insulin (100 nmol/L) were similar in angioblasts from TG and WT mice (Fig. 8D) as assessed by FACS using antibodies to pAkt. Similarly, HF feeding did not affect pAkt levels in angioblasts from WT or ECIRS1TG mice. Unlike angioblasts, insulin-induced pAkt levels in ECs from GT were significantly higher, by 196%, in ECIRS1TG mice compared with WT mice (Fig. 8E). In contrast, insulin-induced pAkt levels only increased by 127% in ECs isolated from HF-fed ECIRS1HF compared with WTHF mice (Fig. 8E). Unlike the angioblasts, the levels of pAkt were significantly lower, by 50%, in the ECs of GT from ECIRS1 HF mice versus from WT mice on NC (Fig. 8E). Similarly, pAkt levels in the ECs from ECIRS1 HF were decreased by 64% versus ECIRS1 TG mice. Nevertheless, insulin-induced pAkt levels in ECs from ECIRS1 HF mice were still significantly higher than those from WTHF mice, by 107% (Fig. 8E). The levels of pAkt stimulated by VEGF (2.5 ng/mL) in angioblasts from GT were significantly higher in WT mice compared with WTHF mice (Fig. 8F).
This study demonstrated that enhancing insulin actions in the ECs can improve wound healing in nondiabetic, diabetic, and insulin-resistant states when insulin is present. Further, we have identified a novel defect in the differentiation of angioblast to EC with a parallel reduction of insulin-induced pAkt as a potential mechanism for the deficiency in angiogenesis in the GT induced by diabetes and insulin resistance.
Our study confirmed that diabetes, whether due to insulin deficiency or insulin resistance by HF diet, can impair both angiogenesis and the wound healing process (6,38,39). However, mechanisms causing the impaired wound healing process may be different when diabetes is due to insulin deficiency or obesity and insulin resistance. In the insulin deficiency model, enhancement of insulin action in the ECs did not have any beneficial effects on wound healing, which supports the conclusion that the improvement in ECIRS1 TG mice was likely due to the enhancing of insulin’s actions in the ECs of the GTs. Evaluation of the GT in ECIRS1 TG mice showed a sequential elevation of VEGF, FLK1, and VE-cadherin expressions after the initial injury compared with WT mice. These findings strongly supported the idea that improving insulin’s actions in ECs enhanced VEGF expression and its signaling cascades to improve angiogenesis and wound healing. It is also possible that insulin may have perivascular effects due to its specific action on the ECs, such as the activation eNOS, to elevate NO and blood flow from the increases in angiogenesis to enrich the cells of the GT and improve wound healing (20,33,34,40). Further, increased blood flow to GT has been reported to improve the influx of inflammatory cells, which can enhance angiogenesis (21). Clearly, the elevated VEGF expression in the GT observed in ECIRS1 TG mice is likely due to the enhancement of insulin signaling through the IRS1/PI3K/Akt pathway, which has been shown to regulate VEGF expression in ECs (14,40,41).
The reduced VEGF expression in the GT from STZ-induced diabetic mice, which has been reported, is likely due to insulin deficiency (3,6,42). This conclusion is supported by the findings of the paradoxical increases of VEGF expression in GT from mice with HF-induced diabetes, which exhibited hyperinsulinemia rather than insulin deficiency. Hyperinsulinemia may induce VEGF not only in ECs but from fibroblasts and inflammatory cells (14,42). The paradoxical findings of VEGF expression in GT indicate that the impaired angiogenesis in wound healing may have different pathogenic mechanisms for insulin-resistant and deficiency-induced diabetes. This study provided the first direct comparative analysis of GT and wound healing between insulin-deficient and hyperinsulinemic and insulin-resistant models of diabetes. A previous report showed that VEGF expression in whole wound from HF-fed mice was similar to control diet, but higher than ob/ob diabetic mice (39).
Interestingly, HF-induced obesity clearly caused defects in GT formation and angiogenesis with decreased capillary density, even in the presence of hyperinsulinemia, and elevated VEGF levels, suggesting the possibility of resistance to insulin or VEGF actions in the GT of WTHF or ECIRS1HF mice. Analysis of GT cells indicated that enhancing EC’s insulin action increased both angioblasts and ECs. Interestingly, diabetes and insulin resistance inhibited only ECs and not angioblasts in the GT numbers. This provided the first identification that defect in capillary formation in GT induced by diabetes or insulin resistance is partly due to a selective inhibition in the differentiation of angioblasts to ECs. Further, the reduction of ECs could only be partially normalized by improving insulin’s signaling in the ECs, even though VEGF levels were elevated in HF conditions. Our results also provide evidence that insulin can have actions on angioblasts, as shown by increasing DNA synthesis of angioblasts in the GT of ECIRS1 TG mice may not be inhibited by obesity or diabetes since angioblast numbers were not changed in these states. The effect of insulin to increase angioblasts and ECs in the GT was the result of elevating in situ cellular proliferation since there were no increases in the uptake from infused GFP-labeled angioblasts or ECs in WT or ECIRS1 TG mice. Signaling studies indicated that HF diet–induced selective inhibition of insulin induced pAkt in the ECs but not in the angioblasts, which is consistent with the finding that HF diet did not decrease the number of angioblasts but only the ECs. These findings confirmed the idea that diabetes and insulin resistance caused a selective defect in the differentiation of angioblasts to ECs. By using the VE-cadherin promotor, IRS1 overexpression is limited to ECs and not in angioblasts, which do not express VE-cadherin (43). This approach may not enhance angioblast differentiation to ECs, which appears to be abnormal also in diabetes. This study suggests that angioblasts are sensitive to insulin. Previously, Schatteman et al. (44) reported that circulating angioblasts responded initially to insulin at 6–12 μg/mL, but they become resistant after prolonged exposure, which the authors suggested is the reason that the hyperinsulinemia of type 2 diabetes could be causing poor angiogenesis in wound healing. However, the level of insulin used by Schatteman et al. (44), was ≈1 μmol/L, which is much higher than physiological levels (<10 nmol/L), which makes the finding difficult to interpret for in vivo studies.
These studies provide documentation that diabetes caused by insulin deficiency or diet-induced obesity can induce a selective abnormality in the differentiation of angioblasts to ECs in the GT, which is related to resistance of pAkt activation induced by insulin and possibly VEGF. Detailed studies to understand the mechanisms that are causing the inhibition of insulin or VEGF activation of pAkt in the GT in diabetes will need to be performed in the future. Further, we also observed that enhancing insulin action specifically in the ECs through the IRS1/PI3K/pAkt pathway could improve wound healing both in nondiabetic and obesity-induced diabetes, suggesting a new therapeutic target for wound healing.
Acknowledgments. The authors thank Scott Gordon at the Joslin Diabetes Center for the preparation of the manuscript.
Funding. S.K. is the recipient of a research fellowship (Hiroo Kaneda Scholarship, Sunstar Foundation, Japan). Support was also provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Diabetes Research Center grant P30DK036836 and Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (26463128). This work was also supported by NIH/NIDDK grant R01 DK053105-13 to G.L.K.
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Author Contributions. S.K. performed most of the experiments and wrote the first draft of the manuscript. K.P., Y.M., M.K., Q.L., and H.Y. assisted in some studies and reviewed the manuscript. T.N.R. and A.W. provided advice on the analysis of the angioblasts and ECs from GT and BM. A.M. made the ECIRS1 TG mouse. L.L. and D.P.O. provided expertise on the wound healing model. G.L.K. conceived the project, designed the experiments, supervised all studies, and wrote the manuscript. G.L.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1721/-/DC1.
- Received December 17, 2015.
- Accepted May 15, 2016.
- © 2016 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://diabetesjournals.org/site/license.